BCIQ Profiles

Company Profile Report

Durect looks ahead to liver indications after Phase IIa miss in psoriasis

Although the failure of topical DUR-928 in a Phase IIa psoriasis trial vaporized more than a quarter of Durect’s market cap on Thursday, the company is pressing on

Read the full 280 word article

How to gain access

Continue reading with a
two-week free trial.